We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Sciences Claims Remdesivir Reduces COVID-19 Mortality Risk
Gilead Sciences has said its antiviral Veklury (remdesivir) reduced hospitalization and death rates for COVID-19 patients, based on new results from three real-world studies.